Bristol Myers Squibb is already aiming to launch more than 10 new medicines by 2030. | SAN FRANCISCO—Bristol Myers Squibb is ...

Agno Pharma, a global contract development and manufacturing organization (CDMO) specializing in small-molecule active ...

Dr. Maki brings nearly 20 years of biotechnology and pharma business development expertise as Company rapidly advances its powerful LNP platform to deliver mRNA-based therapies MENLO PARK, Calif. & ...

Filippo Mulinacci joined Araris Biotech in 2022 as its chief business officer. In March, the oncology company, based in Zurich, Switzerland, was acquired by Taiho Pharma, based in Tokyo, as part of a ...

Bain Capital has agreed to acquire Mitsubishi Chemical Group’s pharmaceutical business for more than $3 billion, a deal that ...

At Bayer, a groupwide restructuring is being rolled out as a top priority. But, to Juergen Eckhardt, M.D., who leads both the investment arm Leaps by Bayer and the pharma business development team, ...

Bioprinting is rapidly moving from research labs into commercial reality, and it is reshaping how the pharmaceutical and biotechnology industries think about drug development, regenerative medicine, ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva’s anti-IL-15 candidate TEV-‘408 TEV- ...

WASHINGTON — Redwire is making a bigger push into space pharmaceutical development with a new business entity devoted to the field. Redwire announced Aug. 4 the creation of SpaceMD, an entity that ...

Chinese drugmaker Jiangsu Hengrui Pharmaceuticals has agreed to develop up to 12 of its drugs with British pharmaceutical giant GSK. Hengrui Pharma granted GSK an exclusive worldwide licence to its ...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Companies seeking to out-license a drug in clinical development will spend an average of $86,000 to identify buyers, according to a recent benchmarking ...

The pharmaceutical industry is a major player in the overall life science sector, responsible for developing and manufacturing the majority of prescription drugs. Companies in this space are ...